Global / Funding

Patient safety startup Graph AI raises $13.3m Series A led by Insight Partners

Pharmaceutical AI automation is attracting large cheques from established venture firms.

Graph AI, which automates workflows for drug safety teams, raised $13.3 million in Series A funding led by Insight Partners with participation from Bessemer Venture Partners. The capital will fund expansion in the US and Europe and accelerate product development.

Published · significance 41 of 100 (low) · 3 independent sources

What happened

Graph AI, founded in 2024, develops Graph Safety, an AI platform that automates pharmacovigilance and patient safety workflows for pharmaceutical and biotechnology companies. The startup raised $13.3 million in Series A funding led by Insight Partners, nearly a year after its seed round in October 2025. The company plans to use the capital to expand internationally and accelerate product development.

Why it matters

Enterprise AI adoption in regulated sectors like pharmaceuticals remains a high-barrier, high-value market. Graph AI's funding signals investor confidence in AI-driven compliance and safety automation, where the stakes for accuracy and liability are substantial. Insight Partners' lead suggests the category attracts institutional capital betting on sustained enterprise spend.

What changes

Graph AI now has runway to build out go-to-market operations in multiple regions and scale its platform to serve larger pharmaceutical and biotech teams. The funding validates the market demand for AI-powered pharmacovigilance automation.

Sources

Written by AI from the reports above; scored by a published formula. How we work. Found a mistake? Email lockedinshreyash@gmail.com. Up To Date summarises and links to original reporting; it never reproduces articles.

Related coverage